Free Trial

Renalytix (RENX) Competitors

GBX 14.36
-1.89 (-11.61%)
(As of 07:42 AM ET)

RENX vs. COG, INHC, FDBK, IQAI, TRLS, DVRG, SENS, EMIS, CRW, and INS

Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.

Renalytix vs.

Cambridge Cognition (LON:COG) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

36.7% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 31.0% of Renalytix shares are owned by institutional investors. 32.0% of Cambridge Cognition shares are owned by company insiders. Comparatively, 35.7% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Cognition£12.77M1.12-£3.74M-£0.10-406.70
Renalytix£2.41M8.79-£41.85M-£0.30-47.88

Cambridge Cognition received 82 more outperform votes than Renalytix when rated by MarketBeat users. However, 74.19% of users gave Renalytix an outperform vote while only 44.30% of users gave Cambridge Cognition an outperform vote.

CompanyUnderperformOutperform
Cambridge CognitionOutperform Votes
105
44.30%
Underperform Votes
132
55.70%
RenalytixOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

Cambridge Cognition has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company Overall Sentiment
Cambridge Cognition Neutral
Renalytix Neutral

Renalytix has a net margin of 0.00% compared to Renalytix's net margin of -29.25%. Renalytix's return on equity of -630.55% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Cognition-29.25% -630.55% -13.31%
Renalytix N/A -651.40%-88.32%

Summary

Cambridge Cognition beats Renalytix on 7 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RENX vs. The Competition

MetricRenalytixHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£21.19M£228.45M£5.10B£1.40B
Dividend YieldN/A6.27%5.25%11.82%
P/E Ratio-47.88666.96114.191,680.88
Price / Sales8.79647.312,304.45268,300.38
Price / Cash1.8437.0431.4232.84
Price / Book-1.804.054.722.73
Net Income-£41.85M-£6.75M£108.12M£165.77M
7 Day Performance-17.36%0.49%0.25%0.05%
1 Month Performance-22.36%-2.03%-3.10%7.21%
1 Year Performance-82.59%-4.08%-2.96%23.18%

Renalytix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COG
Cambridge Cognition
0 of 5 stars
GBX 41
flat
N/A-60.1%£14.41M£12.77M-410.0080High Trading Volume
INHC
Induction Healthcare Group
0 of 5 stars
GBX 11.50
flat
N/A-51.0%£10.62M£11.82M-76.6783High Trading Volume
FDBK
Feedback
0 of 5 stars
GBX 75
flat
N/A-31.8%£10.00M£1.02M-288.4624
IQAI
IQ-AI
0 of 5 stars
GBX 1.20
flat
N/A-58.6%£2.66M£538,190.00-13.676
TRLS
Trellus Health
0 of 5 stars
GBX 1.45
-6.5%
N/A-77.6%£2.34M£35,000.00-48.3331Gap Down
High Trading Volume
DVRG
DeepVerge
0 of 5 stars
N/AN/A+0.0%£1.14M£12.41M-15.0073
SENS
Sensyne Health
0 of 5 stars
N/AN/AN/A£583,000.00£7.81M-0.0270Gap Down
EMIS
EMIS Group
0 of 5 stars
GBX 1,920
flat
N/A+41.6%£1.23B£176.86M4,085.111,560
CRW
Craneware
0.44 of 5 stars
GBX 2,300
flat
GBX 2,600
+13.0%
+56.1%£812.36M£180.56M10,952.38734
INS
Instem
0 of 5 stars
GBX 830
flat
N/A+31.7%£199.62M£61.63M5,928.57500

Related Companies and Tools

This page (LON:RENX) was last updated on 6/25/2024 by MarketBeat.com Staff

From Our Partners